You are here

Synthesis and Characterization of Polymeric Antioxidant microparticles for the pr

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI106266-01A1
Agency Tracking Number: R43AI106266
Amount: $300,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-123
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
11189 Sorrento Valley Rd, Suite 104
SAN DIEGO, CA 92121-
United States
DUNS: 962535782
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (919) 559-3653
Business Contact
Phone: (919) 559-3653
Research Institution

DESCRIPTION (provided by applicant): Influenza A viruses are a major global health concern. Despite annual vaccination programs in the US, 10-15% of the population is infected annually accounting for an estimated 36,000 deaths and 200,000 hospitalizations.Two classes of antiviral drugs have been approved for influenza prophylaxis and treatment. Alarmingly, the past decade has witnessed the emergence of drug-resistant as well as novel 2009 pandemic (H1N1) and highly pathogenic (H5N1) strains of influenza A.Amantadine-resistance has become so widespread the adamantanes have become all but ineffective. Significant resistance to neuraminidase inhibitors has also been observed in some influenza A strains. Thus, there is an urgent need for new and more effectiveantiviral therapies. Optimally, as adopted for the treatment of other viral diseases, combination drug therapies would be used to provide the most effective prophylaxis and treatment and to inhibit the emergence of drug-resistance. Here we propose to optimize potency and cytotoxicity properties of identified novel hit series compounds that overcome current drug-resistance mechanisms to inhibit both amantadine-sensitive and -resistant forms of the M2 proton channel. Optimization of these chemical series could provide novel broad-spectrum therapeutics for new mono- and combination antiviral drug therapies for influenza A; a designated NIAID high priority area of interest. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Over the past decade, the emergence of drug-resistant and/or highly pathogenic variants of influenza A has substantially increased the potential impact of both seasonal and pandemic influenza infection. This proposal details a novel approach to provide much-needed novel inhibitors and potential therapeutics for the prevention and treatment of influenza A infection.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government